Principal Investigator
Macarena De La Fuente
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220774
Clinical Trial Summary
A Phase 1, Safety Lead In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Neurological Cancer
Contact Information
Phone Number
305-243-2647